CliffBio
small molecule

KEPPRA

LEVETIRACETAM

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameKEPPRA
Active ingredientLEVETIRACETAM
Strength500MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1999
Marketing statusRX

Listed patents

PatentExpiresType
8802142*PEDDecember 2031—
8802142June 2031product

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KEPPRA patent cliff — loss of exclusivity December 2031 | CliffBio